Why Specialty Medicine Access Varies So Much Between Countries

A medicine approved in one country is not automatically available in another. The gap between approval somewhere and access where a patient actually lives is often measured in years, and sometimes it never closes.

Understanding why helps in navigating it.

Registration is country by country

There is no global approval. A manufacturer must apply to each national regulator separately, and applying costs money and takes time. Where a market is small or the commercial case is weak, the application may simply never be made.

This is the first and largest barrier. A medicine that is not registered in a country cannot normally be sold there, however well established it is elsewhere.

Pricing and reimbursement

Registration alone does not mean patients can get it. Most health systems then negotiate price, and assess cost-effectiveness before agreeing to fund a treatment.

Those negotiations fail sometimes. A medicine can be legally available and practically inaccessible because nothing covers the cost.

Procurement and supply

Even funded medicines run out. Specialty products often have a single manufacturing site, and a problem at that site becomes a global shortage. Smaller markets are typically de-prioritised when allocation decisions are made.

What this looks like in practice

• A cancer therapy standard in one country, unregistered in the next
• Waiting lists driven by budget cycles rather than clinical urgency
• Regional variation within a single country
• Repeated shortages of an older, cheap, essential medicine

Routes that exist

Where a medicine is not available locally, several legitimate routes may apply — which ones depends entirely on national law:

• Named-patient or compassionate use — a manufacturer supplies an unlicensed medicine for a specific patient, on a physician's request
• Expanded access programmes — for medicines still in development
• Personal importation — permitted in many countries within limits, covered in our guide to importing prescription medicine
• Clinical trial participation — sometimes the only route to a very new therapy

A treating physician is the right starting point for all of these. They are also the only person who can write the documentation each requires.

Language is an access barrier too

A patient reading a leaflet in an unfamiliar language, or negotiating with a supplier who does not share one, is at a disadvantage that has nothing to do with cost or regulation. Product information in a language the patient actually reads is a safety matter, not a courtesy.

It is why our catalogue carries English, Chinese and Spanish throughout.

What helps

• Ask the treating physician directly what access routes exist locally
• Contact patient organisations for the specific condition — they usually know the practical routes better than anyone
• Confirm your country's importation rules from an official source before ordering anything
• Verify any supplier carefully; see how to check a medicine is genuine
• Plan reorders early, because the delay is the part you cannot control

Browse the full catalogue or ask about a specific medicine.

This article is general information, not medical advice. Treatment decisions belong with a qualified clinician who knows your history. Every medicine mentioned is prescription-only and requires a valid prescription.